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Introduction
Women who have mutations in the BRCA1 gene have an 
increased lifetime risk of  developing hereditary breast and ovarian 
cancers. BRCA1 mutations are responsible for up to 10% of  the 
epithelial ovarian cancers (EOC) and 15% of  breast cancers [1, 
2]. Epithelial ovarian cancers are typically of  the serous subtype 
and can be subdivided into two categories: Type I and Type II 
tumors. Type I is considered a low-grade tumor, whereas type II 
is considered a high-grade tumor; type II is the most malignant 
form of  ovarian cancer accounting for up to 70% of  all ovarian 
cancer diagnoses [3]. The most common and aggressive histotype 
of  epithelial ovarian cancer (EOC), high grade serous carcinoma 
(HGSOC) is associated with germ line BRCA1 mutations with a 
lifetime risk of  40-60% [4]. Over 75% of  breast tumors found in 
women with a BRCA1 mutation have a so-called triple negative 
phenotype (TNBC), meaning that these tumors do not express 
estrogen receptor, progesterone receptor and human epidermal 
growth factor receptor type 2 (HER2) [5]. A high percentage of  
BRCA1-associated hereditary and sporadic breast cancers are 
triple negative and are more likely to occur among pre-menopausal 
women of  African American descent [6]. For women of  African 
American descent there is a low survival rate for individuals that 
have advanced EOC or TNBC due to lack of  treatment for 
advanced epithelial ovarian cancer and no targeted treatment 
for TNBC. Therefore, there is a critical need for better targeted 
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therapies for these high grade TNBC and ovarian cancers [7-9].
We have identified and cloned two major splice variants of  
BRCA1, namely BRCA1a/p110 and BRCA1b/p100 [10, 11], 
both are expressed at lower levels in ovarian and breast tumors 
as opposed to normal cells [12-15]. Although, the mechanism of  
tumor suppression remains unknown, we found BRCA1a protein 
to induce apoptosis and inhibit in vivo tumor growth of  CAL51 
TNBC and hormone-independent ES-2 ovarian cancer cells [16, 
17]. BRCA1 promoter hyper methylation has been identified as 
an important mechanism for BRCA1 inactivation in sporadic 
breast cancer and appears to correlate with reduced BRCA1 
mRNA and protein. Recent integrated analyses of  messenger 
RNA expression, microRNA expression, DNA methylation and 
DNA copy number aberrations have shown that more than 30% 
of  high-grade serous ovarian carcinomas and basal-like breast 
cancers had a dysfunctional BRCA pathway as a consequence of  
germline or somatic BRCA1/2 mutations or BRCA1 promoter 
hyper methylation [5]. BRCA1 and its splice variants are nuclear 
proteins that contain several functional domains, an N-terminal 
RING finger domain that interacts with several proteins and two-
BRCA1 C-terminal domains involved in transcriptional activation. 
BRCA1, BRCA1a and BRCA1b proteins are nuclear-cytoplasmic 
shuttling proteins that are also localized in the mitochondria [10, 
15, 18, 19]. The action of  nuclear localization signals (NLS) and 
nuclear export signals (NES) located in the RING domain that 
mediates nuclear transport via association with BARD1 are also 
responsible for the regulation of  BRCA1 nuclear transport [20]. 
The BRCA1 delta isoform, which lacks NLS, also enters the 
nucleus via the RING-domain mediated BARD1 import pathway 
[21]. The RING domain of  BRCA1, in complex with BARD1, 
mediates an E3 Ubiquitin ligase activity on ER-α in-vitro [21, 22]. 
Using an Ubiquitin ligase-deficient BRCA I26A mutant, recent 
findings suggest that the Ubiquitin ligase activity is expendable 
for both, genomic stability and homology-directed repair of  
double-strand DNA breaks, however the Ubiquitin ligase activity 
is essential for repression of  ER-α activity [23, 24].
Many proteins are known to undergo post-translational 
modifications which play a major role in regulating gene expression 
[25]. SUMO (Small Ubiquitin-like modifier) modification of  
proteins is a dynamic and reversible process that affects several 
functions like stability, localization, protein-protein interactions 
and transcriptional regulation [26-28]. The SUMO modification 
pathway was shown to be involved in BRCA1 response to DNA 
damage and transcriptional repression [29, 30]. We have shown 
the amino-terminal domain of  BRCA1, BRCA1a and BRCA1b 
proteins to bind to SUMO-E2-conjugating enzyme Ubc9 and 
regulate ER-α activity by promoting its degradation in vivo [31]. 
This work suggested that there is a cross talk between the SUMO 
and Ubiquitin pathways, similar to the Ubiquitin ligase RNF4, 
by highlighting a new biochemical function of  BRCA1 as a 
putative SUMO-1 and Ubc9-dependent E3 Ubiquitin ligase for 
ER-α SUMO conjugates [32, 33]. Ubc9 binding site mutations, 
as well as cancer-predisposing mutation in the BRCA1 RING 
domain (C61G), disrupted the ability to modulate Ubc9-mediated 
estrogen-induced ER-α transcriptional activity in breast cancer 
cells [31] but did not disrupt SUMO-1 binding [29] nor auto 
ubiquitination activity of  BRCA1 [31]. Both BRCA1/BRCA1a 
K109R and disease associated C61G mutants, which are localized 
mainly in the cytoplasm, fail to suppress the growth of  TNBC 
and ovarian cancer cells [34]. Ubc9 has been shown to play an 
important role in both tumor progression and resistance to 
chemotherapy [35-38]. In fact, Ubc9 was found to act as both a 
positive and negative regulator of  proliferation and transformation 
of  HMGA1 proteins [39]. Here, we have further investigated 
these findings in physiologically relevant BRCA1 germ line mutant 
TNBC and HGSOC cell lines obtained from patients. Using these 
cells we have studied the in vivo association of  BRCA1 with Ubc9, 
expression of  Ubc9 in these BRCA1 mutant TNBC and HGSOC 
cell lines and tumor tissues. We have also studied the effect of  
knock-down of  Ubc9 on proliferation and migration of  these 
cells. Our data suggests SUMOylation pathway to be a potentially 
important candidate for targeted therapy for BRCA1 associated 
TNBC and HGSOC.
Materials and Methods
Cell Culture 
MCF10A, HCC1937, UWB1.289 and UWB1.289 BRCA1 cells 
were obtained from American Type Culture Collection (Rockville, 
MD, USA) and cultivated as described previously [34, 40, 41]
HCC1937 cells were grown in RPMI 1640 medium with 20% FBS 
and 1% PS.
Western blot analysis
MCF10A, HCC1937, UWB1.289 and UWB1.289 BRCA1 cells 
were seeded into 10 cm Petri-dishes with a density of  2 x 106. 
After 48 hours the cell pellets were lysed in SUMO lysis buffer 
(62.5 mM Tris-HCl, pH 6.8, 2% SDS) and the proteins were 
separated on 4-20% gradient SDS-PAGE and transferred to 
nitrocellulose membrane. The primary antibodies for BRCA1 
(Calbiochem, AB-1, mAb, 1:100), Ubc9 (Abcam, ab21193, pAb, 
1:1000), Ubc9 N-15 and β-Actin (Santa Cruz C4, 1/1000) were 
used to probe the proteins of  interest. The protein bands were 
visualized by Image Reader LAS-3000 (FUJIFILM) using HRP 
labeled secondary antibody to mouse or goat and developing 
solution (GE Healthcare). The signal of  Ubc9 protein band was 
quantified using software MultiGauge. The values are standardized 
with the internal control β-Actin, UWB1.289 is defined as 1. Bars 
represent the mean ± SE of  at least two experiments. For western 
blot analysis using patient tissue samples, Ubc9 protein levels were 
screened in seven patient sets of  papillary adenocarcinomas/
normal adjacent tissue lysates using INSTA-blot ovary tissue 
OncoPair from INGENEX. For the blot the tissue specimens 
were homogenized in modified RIPA buffer to obtain the soluble 
proteins and centrifuged to clarify. Sample buffer was added to 
the soluble fraction and approximately 14 µg/lane of  protein 
was run and then transferred to PVDF membrane. The blot was 
probed with the Ubc9 primary antibody (Santa Cruz N15, 1/100) 
and HRP labeled secondary antibody to goat and developing 
solution (GE Healthcare). The bands were visualized by Image 
Reader LAS-3000 (FUJIFILM) as before.
Antibodies and reagent 
The antibodies used in this study were MS110 ascites (Ab1, 
EMD Chemicals), Ubc9 N-15, β-Actin antibodies (Santa Cruz 
Biotechnology) and Ubc9 ab21193 (Abcam).
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Immunofluorescence microscopy 
 MCF10A, HCC1937 and UWB1.289 and UWB1.289 BRCA1 cells 
were cultured in six-well plates onto glass coverslips overnight. 
The cells were washed and fixed in icy methanol for 5 minute, 
and blocked using 10% BSA for 60 min, followed by primary 
polyclonal Rabbit anti-Ubc9 antibody 1:150, Monoclonal Mouse 
anti-BRCA1 antibody 1:100 diluted in 1.5 % BSA made in PBS 
at 25°C 1hr and Alexa488 goat anti-Rabbit/Alexa568 goat anti-
mouse (Molecular Probes) diluted in 1.5% BSA/PBS for 50 min 
and stained (Hoechst 33258, Pentahydrate, Life technologies). 
The cover slips were mounted with Vectashield mounting medium 
for fluorescence (H-1000 from Vector). The stained cells were 
examined by LSM 700 Confocal Microscope, equipped with 63X 
oil Ph immersion objectives. Composite filter cubes were used for 
the 488-405 as described previously [41].
RT- PCR analysis
 
UWB1.289 and UWB1.289 BRCA1 cells were seeded into 6-well 
plates with the same density. Forty-eighty hours later, the total 
mRNA was extracted with RNeasy Mini Kit (Qiagen) and the 
first-strand cDNA was synthesized by superscript II Reverse 
Transcriptase (Invitrogen) and the target cDNA was amplified 
by PCR with specific primers for either BRCA1 or Ubc9 and 
visualized by Image Reader LAS-3000 (FUJIFILM). GAPDH 
was used as the internal control. The signal of  Ubc9 RT-PCR was 
quantified using software MultiGauge. The values are standardized 
with the internal control GAPDH, UWB1.289 is defined as 1. 
Bars represent the mean ± SE of  at least two experiments.
siRNA transfection and cell growth analysis
The UWB1.289 cell line was maintained in 50% RPMI and 50% 
MEGM, supplemented with 3% fetal bovine serum. Before 
transfection, UWB1.289 cells were digested with 0.25% of  
Trypsin-EDTA solution and seeded into 6-well plate with a density 
of  1.5x105/well. Twenty-four hours later, dilute Ubc9 siRNA and 
control siRNA (Qiagen) in the culture medium without serum 
(final concentration is 50 nM), HiPerFect Transfection Reagent 
(Qiagen) was added to the diluted siRNA and mixed by vortexing. 
Incubated the mixture for 5–10 min at room temperature (15–
25°C) to allow the formation of  transfection complexes. The 
complexes were added drop-wise onto the cells and gently swirled 
to ensure uniform distribution of  the transfection complexes. The 
cells were incubated for 36 hours and images were taken using a 
fluorescent microscope (Olympus).
Cell proliferation assay using ECIS
The cell growth assays were done using the ECIS (Applied 
Biophysics) technology as described by the manufacturer. The 
UWB1.289 cell line was maintained in 50% RPMI and 50% 
MEGM, supplemented with 3% fetal bovine serum. The Electric 
Cell-substrate Impedance Sensing (ECIS) instrument and culture 
ware 8W10E+ array were purchased from Applied Biophysics 
(Troy, NY). The cells were grown to reach 80% confluence and 
the culture medium was removed, briefly rinsed the cell layer with 
Ca++/Mg++ free Dulbecco's phosphate-buffered saline (D-PBS), 
the cells were digested with 0.25% of  Trypsin-EDTA solution 
and observed under an inverted microscope until cell layer was 
dispersed (usually within 5 to 15 minutes). The trypsin digestion 
of  the cells was terminated with the complete growth medium 
aspirated by gentle pipetting and counted. The total cell number 
of  8x104 of  UWB1.289 cells were seeded into the 8W10E+ 
array and transfected with Ubc9 siRNA or control siRNA (100 
nM) (Qiagen) and pre-warmed in the CO2 incubator until the 
temperature of  the cell suspension reached 37ºC. The array was 
then connected to the ECIS instrument electrode. The instrument 
was set to record the cell growth behavior with time course as 
described by the manufacturer.
Migration assay
To perform migration assays 2 x 105 ES-2, HCC1937 and 
CAL51 cells were plated into 6-well cell culture plate. Cells were 
transfected with 100 nM of  Ubc9 siRNA or control siRNA using 
Qiagen kit as described by the manufacturer. After 24 hours a 
1mm wide scratch was made across the cell monolayer using a 
sterile 200 µl pipette tip. Cells were allowed to grow in normal 
medium for 24 hours to 48 hours. Plates were photographed at 
0 h immediately after scratch and 24 hours or 48 hours following 
scratching as needed. All experiments were repeated at least twice.
Results
Loss of  association of  BRCA1 and Ubc9 in BRCA1 mutant 
HGSOC and TNBC cells
Wild Type BRCA1 but not the disease associated mutants have 
been shown to bind in vitro to SUMO E2 conjugating enzyme 
Ubc9 and this is responsible for both ER-alpha activation and 
tumor suppression of  breast and ovarian cancer cells [31, 34]. 
To examine whether this occurs in vivo, we have studied the 
association of  BRCA1 and Ubc9 in normal mouse mammary 
epithelial cells MCF10A and a basal-like TNBC cell line HCC1937 
obtained from a patient with germ line BRCA1 mutation using 
immunofluorescence analysis. Our results show in vivo association 
of  BRCA1 and Ubc9 in MCF10A but not in HCC1937 cells 
(Figure 1A). Similarly we have studied the in vivo association of  
BRCA1 and Ubc9 in a HGSOC cell line UWB1.289 obtained 
from a patient with BRCA1 mutation and BRCA1 reconstituted 
UWB1.289 cells by immunofluorescence analysis using BRCA1 
and Ubc9 antibodies. Our results show localization of  BRCA1 
and Ubc9 in UWB1.289 BRCA1 cells but not in the UWB1.289 
cells (Figure 1B). These results support our previous hypothesis 
that lack of  association of  BRCA1 with Ubc9 could be responsible 
for the development of  TNBC and HGSOC.
Ubc9 is expressed at elevated levels in BRCA1 mutant 
HGSOC, TNBC cells and ovarian tumor tissues
To examine whether lack of  binding of  mutant BRCA1 to Ubc9 
in HCC1937 TNBC cells and UWB1.289 HGSOC cells results 
in upregulation of  Ubc9, we investigated Ubc9 expression in 
these cell lines. For this we subjected UWB1.289 and UWB1.289 
BRCA1 cells to western blot analysis using BRCA1 and Ubc9 
antibodies. We also isolated RNA from these cells and performed 
BRCA1 and Ubc9 cDNA amplification by PCR using their 
respective primers. Our results showed inverse correlation 
between BRCA1 expression and Ubc9 levels both at the protein 
as well as RNA level (Figure 2 A, B, C and D). Similarly we studied 
the expression of  Ubc9 in both MCF10A and HCC1937 cells by 
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Figure 1. Co-localization of  endogenous Ubc9 with endogenous BRCA1 in normal mammary epithelial cells MCF10A and 
UWB1.289+BRCA1 cells but not in BRCA1 mutant SEOC cells UWB1.289 and BRCA1 mutant TNBC cells HCC1937 ( A 
and B) by immunofluorescence analysis using anti-UBC9 and anti-BRCA1 Antibodies. MCF10A, HCC1937, UWB1.289, 
UWB1.289+BRCA1 cells were cultured in six-well plates onto glass coverslips overnight. They were washed and fixed in 
methanol and blocked using 10% BSA, followed by primary polyclonal Rabbit anti-Ubc9 antibody 1:150 /Monoclonal Mouse 
anti-BRCA1 antibody 1:100 diluted in 1.5% BSA/PBS at 25°C 1hr and Alexa488 goat anti-Rabbit/Alexa568 goat anti-mouse 
(Molecular Probes) diluted in 1.5% BSA/PBS and stained with Hoechst33258. The cover slips were mounted with mounting 
medium. The stained cells were examined by LSM 700 Confocal Microscope, equipped with 63X oil Ph immersion objec-
tives. Composite filter cubes were used for the 488-405.
Figure 2. Ubc9 is expressed at elevated levels in BRCA1 mutant SEOC cells UWB1.289 compared to BRCA1 reconstituted 
UWB1.289 cells. A: Western blot analysis of  BRCA1 and Ubc9 in UWB1.289 and UWB1.289 BRCA1 cell lines. The cells 
were seeded into 10 cm Petri-dishes with a density of  2x106. After 48 hours the cell pellets were lysed in SUMO lysis buffer 
(62.5 mM Tris-HCl, pH 6.8, 2% SDS) and the proteins were separated on 4-20% gradient SDS-PAGE gel and transferred to 
the nitrocellulose membrane. The primary antibodies for BRCA1 (Calbiochem, AB-1, mAb, 1:100), Ubc9 (Abcam, ab21193, 
pAb, 1:1000) and β-Actin (Santa Cruz C4, 1/1000) were used to probe the different proteins of  interest. The protein bands 
were visualized by Image Reader LAS-3000 (FUJIFILM) using HRP labeled secondary antibody to mouse or goat and 
developing solution (GE Healthcare). B: The stoichiometry of  Ubc9 protein levels shown in A. The signal of  Ubc9 protein 
band was quantified using software MultiGauge. The values are standardized with the internal control β-Actin, UWB1.289 
is defined as 1. Bars represent the mean ± SE of  at least two experiments. C: RT-PCR analysis of  mRNA expression of  
BRCA1, Ubc9 and control GAPDH. The UWB1.289 and UWB1.289 BRCA1 cell lines were seeded into the 6-well plate with 
the density of  2x106. Forty-eighty hours later, the total mRNA was extracted with RNeasy Mini Kit (Qiagen) and the first-
strand cDNA was synthesized by SuperScript II Reverse Transcriptase (Invitrogen) and the target cDNA was amplified by 
PCR with specific primers of  either BRCA1 or Ubc9 and visualized by Image Reader LAS-3000 (FUJIFILM). GAPDH was 
used as the internal control. D: The stoichiometry of  Ubc9 mRNA levels is shown in C. The signal of  Ubc9 RT-PCR was 
quantified using software MultiGauge. The values are standardized with the internal control GAPDH, UWB1.289 is defined 
as 1. Bars represent the mean ± SE of  at least two experiments.
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western blot analysis using Ubc9 antibodies. We find increased 
Ubc9 expression in HCC1937 cells compared to MCF10A cells 
(Figure 3 A). We have previously found high Ubc9 expression 
in breast tumors compared to normal matched tissues [34]. We 
studied the expression of  Ubc9 in seven patient sets of  papillary 
adenocarcinomas and adjacent normal tissues by western blot 
analysis using Ubc9 antibody. Our results show enhanced 
expression of  Ubc9 in ovarian tumors compared to matched 
normal tissues (Figure 3 B). This agrees with our results obtained 
using breast tumor tissue samples [34] and previous studies that 
documented higher levels of  Ubc9 expression in several cancers 
compared with their normal tissue counterparts [35-38].
Knockdown of  Ubc9 inhibits proliferation and migration of  
HGSOC and TNBC
Ubc9 has been shown to be upregulated in multiple cancers and 
to promote invasion and metastasis in estrogen receptor positive 
breast cancer cells [35-39]. As mentioned earlier, we observed 
overexpression of  Ubc9 in BRCA1 mutant TNBC cells and 
HGSOC cells. To study whether downregulation of  Ubc9 can 
inhibit the growth and proliferation of  BRCA1 mutant HGSOC 
cells, we suppressed Ubc9 expression in UWB1.289 cells using 
siRNA specific to Ubc9 and measured the growth after 36 
hours using phase contrast microscope (Olympus). As shown in 
Figure 4A, Ubc9 knockdown inhibited the growth of  UWB1.289 
cells unlike the control siRNA transfected cells. We confirmed 
these results using ECIS (electric cell substrate impedance 
sensing) assay. ECIS measurements can be used to monitor cell 
proliferation, and as the cell number increases the amount of  
electrode area covered with the spread cells grows causing the 
electrode impedance to rise. These impedance changes can be 
related to the relative cell proliferation rates. As shown in Figure 
4 B Ubc9 knockdown resulted in inhibition of  growth when 
compared to control siRNA transfected UWB1.289 cells, further 
confirming our previous observations. The expression of  Ubc9 
was efficiently inhibited by Ubc9 siRNA in UWB1.289 cells as 
detected by western blot analysis using Ubc9 antibody (Figure 4 
C). These results suggest Ubc9 to promote cell proliferation of  
BRCA1 mutant HGSOC cells.
To investigate the role of  Ubc9 in ovarian and TNBC cell 
migration we inhibited the endogenous Ubc9 expression using 
Ubc9 siRNA. As shown in Figure 5 Ubc9 siRNA significantly 
inhibited the migration of  ES-2 ovarian cancer cells (Figure 5A), 
HCC1937 BRCA1 mutant TNBC cells (Figure 5 C) and CAL-51 
a non-BRCA1 mutant TNBC cells (Figure 5 D). Ubc9 expression 
was shown to be inhibited by Ubc9 siRNA in ES-2 ovarian cancer 
cells as demonstrated by western blot analysis (Figure 5 B) using 
Ubc9 antibody. These results strongly emphasize a role for Ubc9 
in the migration of  ovarian and TNBC cells.
Discussion
SUMOylation is a dynamic protein modification that regulates 
numerous biological activities of  proteins [42, 43]. Increasing 
studies suggest the SUMO pathway dysregulation in several 
cancers [44]. Recently, there are several reports connecting 
protein SUMOylation and cancer. Elevated levels of  Ubc9 have 
been found in several cancers and are associated with poor clinical 
outcome [45-49]. Our group has previously reported that Wild 
type BRCA1a/1b proteins unlike the pathogenic mutants to 
bind Ubc9, a sole SUMO conjugase and perform its function 
as a tumor suppressor in TNBC and ovarian cancer cells [34, 
41]. Although Ubc9 is ubiquitously expressed in normal cells, 
it was shown to be over-expressed in ovarian, lung, head and 
neck, melanoma and breast cancers [35-38, 44]. In fact, Ubc9 
expression was found to correlate with poor clinical outcome 
in Nigerian women with breast cancer [50]. Here we have used 
two physiological relevant patient derived cell lines obtained 
from BRCA1 mutant TNBC and HGSOC and have shown 
loss of  association of  BRCA1 proteins with Ubc9 in these cells 
unlike normal mammary epithelial cells. Furthermore, we have 
demonstrated that this results in elevated levels of  expression of  
Ubc9 both at the RNA as well as protein levels in these BRCA1 
mutant UWB1.289 ovarian cancer and HCC1937 TNBC cells. 
We have also found that knockdown of  endogenous Ubc9 using 
siRNA resulted in suppression of  cell proliferation and migration 
of  Brca1 mutant TNBC and ovarian cancer cells. In summary, 
Figure 3. A: Ubc9 is expressed at higher levels in BRCA1 mutant TNBC cells HCC1937 compared to normal mammary 
epithelial cells MCF10A. Western blot analysis of  MCF10 A and HCC1937 cells using Ubc9 and actin antibodies. B: Ubc9 
is over expressed in ovarian tumors as compared to matched normal ovarian tissues. Ubc9 protein levels were screened in 
seven patient sets of  papillary adenocarcinomas (lanes 1, 3, 5, 7, 9, 11, 13) and adjacent normal tissue (lanes 2, 4, 6, 8, 10, 
12, 14) lysates using INSTA-blot Ovary. Tissue Onco Pair from IMGENEX. The tissue specimens were homogenized in 
modified RIPA buffer to obtain the soluble proteins and centrifuged to clarify. Sample buffer was added to the soluble frac-
tion and approximately 14 µg/lane of  protein was run and then transferred to PVDF membrane. Soluble fraction extraction 
buffer: PBS at pH 7.4, 1 µg/ml Aprotinin, 1mM NaF modified RIPA buffer: 1mM EDTA, 1 µg/ml pepstatin-A, 0.1% SDS, 
0.25% Na deoxychalate, 1 µg/ml Leupeptin, 1mM PMSF, 1 mM Na3VO4. Ubc9 was probed with the Ubc9 primary antibody 
(Santa Cruz N15, 1/100) and visualized by Image Reader LAS-3000 (FUJIFILM) using HRP labeled secondary antibody to 
goat and developing solution (GE Healthcare).
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Figure 4. Ubc9 knockdown suppresses the cell growth of  ovarian cancer cell line UWB1.289 studied using phase con-
trast microscope (A) and with (B) Electric Cell-substrate Impedance Sensing (ECIS). The same starting cell density of  
UWB1.289 cells (shown in graphs) was seeded into the ECIS cultureware 8W10E+ array (Applied BioPhysics) and transfect-
ed with Ubc9 or control siRNA (100 nM) (Qiagen). The temperature of  the cell suspension was prewarmed to the incubator 
temperature before the array was connected into the instrument electrode. After Setting up the software and the time course 
measurement for cell growth was conducted as described by the manufacturer. (C) Western blot analysis showing Ubc9 
knockdown in ovarian cancer cell UWB1.289. Ubc9 or control siRNA (Qiagen) were transfected into UWB1.289 cells (1x 106) 
using HiPerFect Transfection Reagent (Qiagen) after cells were seeded into the 10cm of  Petri dishes 24 hours. Forty-eight 
hours later, the cells were collected and lysed in RIPA buffer. The cell lysates were probed with primary antibodies either 
Ubc9 (Santa Cruz N15, 1/100) or β Actin (Santa Cruz C4, 1/2000). The proteins were visualized using HRP labeled second-
ary antibody to goat (Ubc9) or mouse (β Actin) and developing solution (GE Healthcare) through Image Reader LAS-3000 
(FUJIFILM).
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we have shown Ubc9 to be required for cancer cell growth and 
migration. These results suggest a molecular interplay between 
BRCA1 and Ubc9 which maintains the balance of  two opposing 
effects: tumor suppression or tumorigenesis. Imbalance in Ubc9 
levels due to BRCA1 mutation can tilt this balance resulting in 
cancer (Figure 6). BRCA1 is a master regulator which by turning 
off  or on Ubc9 binding regulates the normal growth of  a cell. 
These results are consistent with the model that a direct association 
of  BRCA1 with Ubc9 is critical for growth/tumor suppression by 
BRCA1 proteins and lack of  binding results in deregulated Ubc9 
levels causing cancer. Ubc9 has been shown to bind to HMGA1 
proteins and integrate both positive and negative signals for 
proliferation and transformation [39]. Recently, Ubc9 was shown 
to promote cell invasion and metastasis of  breast cancer cells [51] 
implicating a role in tumorigenesis. Several inhibitors of  Ubc9 
have been reported although none are currently in clinical trials 
[52-55]. Future work will address whether TNBC and HGSOC 
with BRCA1 mutations can be selectively eliminated using drugs 
that target Ubc9.
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